187 related articles for article (PubMed ID: 2515603)
1. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
2. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
3. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
6. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
9. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
10. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
11. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
12. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro.
Nishino N; Kakkar VV; Scully MF
Thromb Haemost; 1991 Dec; 66(6):672-7. PubMed ID: 1796413
[TBL] [Abstract][Full Text] [Related]
13. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
[TBL] [Abstract][Full Text] [Related]
14. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of fibrinolytic enzymes in vivo.
Ambrus JL; Weber FJ; Ambrus CM
J Med; 1979; 10(1-2):99-119. PubMed ID: 158624
[TBL] [Abstract][Full Text] [Related]
16. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
Blinc A; Keber D; Lahajnar G; Stegnar M; Zidansek A; Demsar F
Thromb Haemost; 1992 Dec; 68(6):667-71. PubMed ID: 1287880
[TBL] [Abstract][Full Text] [Related]
17. Studies on activator formation in human plasma with streptokinase. III. Investigation of activator kinetics in undiluted plasma in terms of urokinase equivalents.
Martin M
Thromb Haemost; 1976 Dec; 36(3):566-81. PubMed ID: 138962
[TBL] [Abstract][Full Text] [Related]
18. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
Martin M
Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
20. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
